The ABCs of investing in CBD
Consumers have long been interested in the nonpsychoactive chemical in cannabis sativa, cannabidiol, more widely known as CBD. With the passage of the 2018 U.S. Farm Bill legalizing hemp-derived CBD nationwide, more companies are entering the marketplace to offer myriad CBD-laced products that tout everything from pain-relieving properties to lessening anxiety. As interest in going into the CBD business has grown, so has investing in that growth. But as with all potential opportunities, investing — especially in a new concept that has legal parameters — comes with its own set of risks.